Antisperm antibodies: Do antisperm antibodies bound to spermatozoa alter normal reproductive function?

William H. Kutteh

Division of Reproductive Endocrinology, Department of Obstetrics and Gynecology, University of Tennessee, 956 Court Avenue, Room D324, Memphis, Tennessee 38163–2116 USA

Extensive investigations have been conducted to evaluate the potential role of antisperm antibodies (ASA) in infertile men and women. It was originally demonstrated in 1932 that injection of spermatozoa into the peritoneal cavity of female guinea pigs could induce temporary sterilization (Baskin, 1932Go). In the male and female, ASA may be found systemically (in the blood and lymph) and in local secretions (in seminal or cervico–vaginal fluids) (Kutteh et al., 1995Go). Antibodies in the blood and lymph belong predominantly to the immunoglobulin G (IgG) isotype, while those found in external secretions are predominantly of the IgA isotype (Marshburn and Kutteh, 1994Go; Mazumdar and Levine, 1998Go). Many questions still remain on the role of ASA in reproduction (Table IGo). Indeed a recent survey of the diagnosis and management of ASA in the UK indicated little consensus in testing methods, significant levels, and management of ASA (Krapez et al., 1998Go).


View this table:
[in this window]
[in a new window]
 
Table I. Questions concerning antisperm antibodies (ASA) bound to spermatozoa
 
Of particular concern in this age of in-vitro fertilization (IVF) are ASA that may affect the fertilizing capability of male spermatozoa. Autoantibodies to spermatozoa are detected in sera, in seminal plasma, and on spermatozoa. Theoretically, tight junctions between Sertoli cells in the testis form a `blood–testis' barrier which prevents the formation of autoantibodies to spermatozoa. Any break in this barrier (such as after vasovasotomy or genital tract infection) may result in the production of ASA. However, in men, antibodies bound to spermatozoa are not correlated with seminal fluid ASA or ASA in sera (Bronson et al., 1987Go). The question of which test to use for the detection of ASA has previously been discussed (Marshburn and Kutteh, 1994Go; Helmerhorst et al., 1999Go). These detection methods can be divided into three major categories: (i) those which cause agglutination of spermatozoa; (ii) those which cause immobilization of spermatozoa; and (iii) those which detect antibodies specific for spermatozoa. Although there is no consensus, the immunobead test (IBT) and the mixed agglutination reaction (MAR) have emerged as the most frequently-used tests (Krapez et al., 1998Go). In evaluating these methods, one has to consider the source of the sperm antigens. If whole spermatozoa are used, only antibodies directed against antigens contained on the sperm cell surface will be detected. Alternatively, if disrupted or solubilized spermatozoa are used, an entirely different set of antigens will be exposed. Antibodies against these `internal' antigens may not be of biological significance. Another factor influencing these tests is the isotype of detected antibodies (IgG, IgA, or IgM). In some tests IgM is measured; this isotype is found infrequently and in low concentrations in the male reproductive tract (Yeh et al., 1995Go). Others do not measure IgA, the predominant class of antibody found in secretions. An ideal assay for ASA would indicate the location of an antibody (tail-directed or head-directed), would detect each isotype of immunoglobulin (IgG, IgM, and IgA), and would be able to determine a significant level of ASA binding.

Proposed therapies for sperm-bound ASA

ASA may result in a state of subfertility but would rarely prevent fertility completely in couples (Dondero et al. 1979Go; Marshburn and Kutteh, 1994Go). Proposed treatments for subfertility secondary to sperm-bound ASA have evolved in several directions (Table IIGo). These treatments include: (i) methods to reduce the production of ASA (condom use); (ii) processing spermatozoa to decrease the effect of ASA (washing, enzymatic treatment); (iii) separation of ASA bound spermatozoa from non-bound spermatozoa (split ejaculate, depletion); (iv) suppression of antibody production (steroids); and (v) overcoming possible ASA interference (insemination, IVF). Each of these therapies has its advocates. However, in recent years, treatment has advanced to IVF and intracytoplasmic sperm injection (ICSI).


View this table:
[in this window]
[in a new window]
 
Table II. Proposed therapies for male antisperm antibodies (ASA)
 
Possible sites where sperm-bound ASA interfere with IVF

There are many proposed mechanisms for ASA-mediated infertility, but most are thought to act via impairment of processes that lead to oocyte fertilization and embryo development (Haas, 1996Go). Original studies with sperm-bound with ASA demonstrated decreased penetration of the zona pellucida (Haas et al., 1980Go). Experimental data indicate several possible sites where ASA may interfere with IVF (Table IIIGo).


View this table:
[in this window]
[in a new window]
 
Table III. Possible sites that sperm-bound antisperm antibodies (ASA) interfere with in-vitro fertilization
 
A number of studies have been reported which demonstrate the effect of sperm-bound ASA on fertilization rates after IVF (Table IVGo). The majority of these studies appear to indicate deleterious effects of sperm-bound ASA on oocyte fertilization rates, embryo quality, or implantation. However, the majority of the studies that demonstrated deleterious effects were retrospective analyses in patients who had poor fertilization on one cycle of IVF. In most studies, couples with low oocyte fertilization rates and ASA were compared to couples with normal fertilization rates who did not have impaired infertility. Thus, by the design of the study, one would expect significant differences in oocyte fertilization rate, implantation rate, and pregnancy rate (Clarke et al., 1997Go). Relatively few of these studies were performed using a study group tested for ASA in a prospective fashion with selection of control and study patients before the IVF outcome had been determined (Mandelbaum et al., 1987Go; Sukcharoen and Keith, 1995Go; Culligan et al., 1998Go). Interestingly, none of these three studies demonstrated an adverse effect of ASA on IVF (Table IVGo). However, these three studies could be criticized, as their positive criteria for ASA was only >15 or 20% IgG or IgA. World Health Organization guidelines (1992) indicate that `probably significant' levels of ASA are found at >50% binding IgG or IgA.


View this table:
[in this window]
[in a new window]
 
Table IV. Effect of sperm-bound antisperm antibodies (ASA) on in-vitro fertilization. Values in parentheses are precentages
 
Summary and suggestions

In the absence of clear scientific data concerning sperm-bound ASA, most IVF centres have established policies based on their best interpretation of available data. The policy at our unit for the last 2 years has been to screen all male partners for direct ASA (using IBT) prior to IVF. If either IgG or IgA ASA are >50% we have counselled the couple and suggested that half of the oocytes should undergo ICSI. Of course, if other indications for ICSI are present, e.g. prior IVF cycle with <20% fertilization, or low sperm parameters, ICSI would be performed on all oocytes (Hamberger et al., 1998Go). Using this strategy, we identified 14 men with >=50% IgG or IgA ASA out of 215 cases (6.5%), however, there were eight men who otherwise would not have shown indications for ICSI. From these eight couples, four benefited by enhanced fertilization with the ICSI procedure and the other four had no benefit when comparing ICSI with conventional fertilization. In the absence of clear scientific data, many practitioners have used cost effectiveness to determine the usefulness of certain medical strategies. Using the method reported previously (Culligan et al., 1998Go), the cost-benefit ratio of our protocol was calculated. The cost of ASA testing was $21 500 ($100x215 patients) plus the additional charge of ICSI ($1000xeight cases) for a total cost of $29 500. When evaluated based on the four individuals who benefited by ICSI, the total cost per case was $7375 ($29 500 ÷ four couples). An alternative policy might be not to test anyone for sperm-bound ASA and to treat everyone with conventional IVF, unless there were other indications for ICSI. If failed fertilization cycles occurred, a subsequent cycle would be treated with ICSI (as is standard in many centres). If this alternative strategy was used in our centre, the total cost would have been $33 500 for four IVF–ICSI cycles ($8375xfour couples). For a programme of our size the choice of which strategy to use is not clear. Thus, based on the reports summarized above and our own personal experience, therapy for the majority of cases of sperm-bound ASA-associated infertility remains empiric and largely unproven.

Notes

This debate was previously published on Webtrack 82, August 20, 1999

References

Acosta, A.A., van der Merwe, J.P., Doncel, G. et al. (1994) Fertilization efficiency of morphologically abnormal spermatozoa in assisted reproduction is further impaired by antisperm antibodies on the male partner's sperm. Fertil. Steril., 62, 826–833.[ISI][Medline]

Baskin, M.J. (1932) Temporary sterilization by the injection of human spermatozoa. A preliminary report. Am. J. Obstet. Gynecol., 24, 892–897.

Bronson, R.A., Cooper, G.W. and Rosenfeld, D.L. (1987) Seminal fluid antisperm antibodies do not reflect those present on the sperm surface. Fertil. Steril., 48, 505–506.[ISI][Medline]

Byrd, W., Kutteh, W.H. and Carr, B.R. (1994) Treatment of antibody-associated sperm with media containing high serum content: a prospective trial of fertility involving men with high antisperm antibodies following intrauterine insemination. Am. J. Reprod. Immunol., 31, 84–90.[ISI][Medline]

Clarke, G.N., Bourne, H. and Baker, H.W.G. (1997) Intracytoplasmic sperm injection for treating infertility associated with sperm autoimmunity. Fertil. Steril., 68, 112–117.[ISI][Medline]

Clarke, G.N., Lopata, A., McBain, J.C. et al. (1985) Effect of sperm antibodies in males on human in vitro fertilization (IVF). Am. J. Reprod. Immunol. Microbiol., 8, 62–66.[Medline]

Culligan, P.J., Crane, M.M., Boone, W.R. et al. (1998) Validity and cost-effectiveness of antisperm antibody testing before in vitro fertilization. Fertil. Steril., 69, 894–898.[ISI][Medline]

de Almeida, M., Gazagne, I., Jeulin, C. et al. (1989) In-vitro processing of sperm with autoantibodies and in-vitro fertilization results. Hum. Reprod., 4, 49–53.[Abstract]

Dondero, F., Isidori, A., Lenzi, A. et al. (1979) Treatment and follow-up of patients with infertility due to sperm agglutinins. Fertil. Steril., 31, 48–51.[ISI][Medline]

Ford, W.C., Williams, K.M., McLaughlin, E.A. et al. (1996) The indirect immunobead test for seminal antisperm antibodies and fertilization rates at in vitro fertilization. Fertil. Steril., 11, 1418–1422.

Francavilla, F., Romano, R., Santucci, R. et al. (1992) Failure of intrauterine insemination in male immunological infertility in cases in which all spermatozoa are antibody-coated. Fertil. Steril., 56, 587–592.[ISI]

Franklin, R.R. and Dukes, C.D. (1964) Antispermatozoa antibody and unexplained infertility. Am. J. Obstet. Gynecol., 89, 6–9.[ISI][Medline]

Haas, G.G. Jr (1996) Antisperm antibodies in infertile men. J. Am. Med. Assoc., 20, 885–886.

Haas, G.G. Jr, and Manganiello, P. (1987) A double-blind, placebo-controlled study of the use of methylprednisolone in infertile men with sperm-associated immunoglobulins. Fertil. Steril., 47, 295–301.[ISI][Medline]

Haas, G.G., Sokoloski, J.E. and Wolf, D.P. (1980) The interfering effect of human IgG antisperm antibodies on human sperm penetration of zona-free hamster eggs. Am. J. Reprod. Immunol., 1, 40–43.[ISI][Medline]

Haas, G.G. Jr, D'Cruz, O.J.and Genum, B.M. (1988) Effect of repeated washing on sperm-bound immunoglobulin G. J. Androl., 9, 190–196.[Abstract/Free Full Text]

Hamberger, L., Lundin, K., Sjogren, A. and Soderlund, B. (1998) Indications for intracytoplasmic sperm injection. Hum. Reprod., 13, 128–133.[Abstract]

Hamilton, F., Gutlay-Yeo, A.L. and Meldrum, D.R. (1989) Normal fertilization in men with high antibody sperm binding by the addition of sufficient unbound sperm in vitro. J. In Vitro Fertil. Embryo Transfer, 6, 342–344.[ISI][Medline]

Helmerhorst, F.M., Finken, M.J.J. and Ernich, J.J. (1999) Detection assays for antisperm antibodies: what do they test? Hum. Reprod., 14, 1669–1671.[Free Full Text]

Janssen, H.J., Bastiaans, B.A., Goverde, H.J.M. et al. (1992) Antisperm antibodies and in vitro fertilization. J. Assist. Reprod. Genet., 9, 345–349.[ISI][Medline]

Kato, M. (1990) Effect of antisperm antibodies in males on in vitro fertilization. Acta Obstet. Gynaecol. Jpn., 42, 1613–1619.

Katsoff, D., Check, J.H., Bollendorf, A. and Benfer, K. (1995) Chymotrypsin-galactose treatment of sperm with antisperm antibodies results in improved pregnancy rates following in vitro fertilization. Am. J. Reprod. Immunol. 33, 149–154.[ISI][Medline]

Krapez, J.A., Hayden, C.J. Rutherford, A.J. and Balen, A.H. (1998) Survey of the diagnosis and management of antisperm antibodies. Hum. Reprod., 13, 3363–3367.[Abstract]

Kutteh, W.H., Kilian, M., Ermel, L.D. et al. (1994) Antisperm antibodies (ASAs) in infertile males: subclass distribution of IgA antibodies and the effect of an IgA1 protease on sperm-bound antibodies. Am. J. Reprod. Immunol., 31, 77–83.[ISI][Medline]

Kutteh, W.H., Kilian, M., Ermel, L.D. and Mestecky, J. (1995) Antisperm antibodies in infertile women: subclass distribution of immunoglobulin (Ig)A and removal of IgA sperm-bound antibodies with a specific IgA1 protease. Fertil. Steril., 63, 63–70.[ISI][Medline]

Lähteenmäki, A. (1993) In-vitro fertilization in the presence of antisperm antibodies detected by the mixed antiglobulin reaction (MAR) and the tray agglutination test (TAT) Hum. Reprod., 8, 84–88.[Abstract]

Lähteenmäki, A., Reima, I. and Hovatta, O. (1995) Treatment of severe male immunological infertility by intracytoplasmic sperm injection. Hum. Reprod., 10, 2824–2828.[Abstract]

Mandelbaum, S.L., Diamond, M.P. and De Cherney, A.H. (1987) Relationship of antisperm antibodies to oocyte fertilization in in vitro fertilization–embryo transfer. Fertil. Steril., 47, 644–651.[ISI][Medline]

Marshburn, P.B. and Kutteh, W.H. (1994) The role of antisperm antibodies in infertility. Fertil. Steril., 61, 799–811.[ISI][Medline]

Mazumdar, S. and Levine, A.S. (1998) Antisperm antibodies: etiology, pathogenesis, diagnosis, and treatment. Fertil. Steril., 70, 799–810.[ISI][Medline]

Meinertz, H. (1991) Antisperm antibodies in split ejaculates. Am. J. Reprod. Immuol., 26, 110–113.

Menge, A.C. and Black, C.S. (1979) Effects of antisera on human sperm penetration of zona-free hamster ova. Fertil. Steril., 32, 214–218.[ISI][Medline]

Mercan, R., Oehninger, S., Muasher, S.J. et al. (1998) Impact of fertilization history and semen parameters on ICSI outcome. J Assist. Reprod. Genet. 15, 39–45.[ISI][Medline]

Nagy, Z.P., Verheyen, G., Liu, J. et al. (1995) Results of 55 intracytoplasmic sperm injection cycles in the treatment of male-immunological infertility. Hum. Reprod., 19, 1775–1780.

Naz, R.K. (1992) Effects of antisperm antibodies on early cleavage of fertilized ova. Biol. Reprod., 46, 130–139.[Abstract]

Rajah, S.V., Parslow, J.M., Howell, R.J. and Hendry, W.F. (1993) The effects of in-vitro fertilization of autoantibodies to spermatozoa in subfertile men. Hum. Reprod., 8, 1079–1082.[Abstract]

Sukcharoen, N. and Keith, J. (1995) The effect of the antisperm auto-antibody-bound sperm on in vitro fertilization outcome. Andrologia, 27, 281–289.[ISI][Medline]

Shin, D., Palermo, G.D., Goldstein, M. et al. (1998) Indications for corticosteroids prior to epididymal sperm retrieval. Int. J. Fertil. Womens Med., 43, 165–170.[ISI][Medline]

Sharma, K.K., Barratt, C.L., Pearson, M.J. and Cooke, I.D. (1995) Oral steroid therapy for subfertile males with antisperm antibodies in the semen: prediction of the responders. Hum. Reprod., 10, 103–109.[Abstract]

Vazquez-Levin, M.H., Notrica, J.A., de Fried, E.P. (1997) Male immunologic infertility: sperm performance on in vitro fertilization. Fertil. Steril., 68, 675–681.[ISI][Medline]

Witkin, S.S., Viti, D., David, S.S. et al. (1992) Relation between antisperm antibodies and the rate of fertilization of human oocytes in vitro. J. Assist. Reprod. Genet., 9, 9–13.[ISI][Medline]

World Health Organization. (1992) WHO Laboratory Manual for the Examination of Human Semen and Semen–Cervical Mucus Interaction. 3rd edn. Cambridge University Press, Cambridge, UK.

Yeh, W.R., Acosta, A.A., Seltman, H.J. and Doncel, G. (1995) Impact of immunoglobulin isotype and sperm surface location of antisperm antibodies on fertilization in vitro in the human. Fertil. Steril., 63, 1287–1292.[ISI][Medline]

Zouari, R., de Almeida, M., Rodrigues, D. and Jouannet, P. (1993) Localization of antibodies on spermatozoa and sperm movement characteristics are good predictors of in vitro fertilization success in cases of male autoimmune infertility. Fertil. Steril., 59, 606–612.[ISI][Medline]